Christine Lu-Emerson, MD
Neurology · Scarborough, MENPI 1336254259
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,140 of the $4,411 with a category attached, or 93.9%. Janssen Research & Development, LLC accounts for 93.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $3,865 and has fallen 97.8% since, to $86 in 2022.
Across 5 payments — averaging $882.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$4K
- Agios Pharmaceuticals, Inc.$185
- Novocure Inc.$86
Across 111 payments — averaging $34,715 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$3.6M
- Novocure GmbH$197K
- Janssen Research & Development, LLC$63K
- Servier Pharmaceuticals LLC$28K
- Agios Pharmaceuticals, Inc.$11K
- AbbVie$2K
What the payments were for
- Consulting fees$4,14094%
- Food & beverage$2716%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 2 | $4,140 |
| Agios Pharmaceuticals, Inc. | 1 | $185 |
| Novocure Inc. | 2 | $86 |
How this compares
$4,411 in reported general payments places this provider in the 80th percentile of 69 neurology providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KoselugoSelumetinib Sulfate | 13 | $311,696 |
| Nurtec OdtRimegepant Sulfate | 11 | $17,513 |
| Lamotrigine ErLamotrigine | 53 | $16,887 |
| Levetiracetam | 154 | $9,902 |
| Lacosamide | 42 | $6,255 |
| Divalproex Sodium ErDivalproex Sodium | 24 | $4,413 |
| Levetiracetam ErLevetiracetam | 29 | $3,599 |
| Carbamazepine ErCarbamazepine | 15 | $1,909 |
| Gabapentin | 66 | $1,663 |
| Lamotrigine | 63 | $1,663 |
| Memantine Hcl | 28 | $1,372 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 13 | $1,219 |
| Oxcarbazepine | 13 | $535 |
| Dexamethasone | 24 | $400 |
| Zonisamide | 11 | $339 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scarborough
- Heidi HenningerScarborough$350K
- Helia MaghziScarborough$37K
- Edward DrasbyScarborough$22K
- Dustin SmythScarborough$1K
- Jacob StoutScarborough$685
- Paul MuscatScarborough$471
- Tamara SchwartzScarborough$231
- Eric DinnersteinScarborough$197
- Diana GoodmanScarborough$180
- Will Valenti-MckeenScarborough$146
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.